(DRW3) Drägerwerk & Co. KGaA (pref) - Ratings and Ratios
Ventilators, Gas Detectors, Patient Monitors, Respirators, Incubators
Dividends
| Dividend Yield | 2.99% |
| Yield on Cost 5y | 3.49% |
| Yield CAGR 5y | 47.53% |
| Payout Consistency | 77.7% |
| Payout Ratio | 31.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 28.1% |
| Value at Risk 5%th | 40.4% |
| Relative Tail Risk | -12.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.37 |
| Alpha | 53.10 |
| CAGR/Max DD | 0.94 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.839 |
| Beta | 0.031 |
| Beta Downside | 0.421 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.32% |
| Mean DD | 8.57% |
| Median DD | 8.62% |
Description: DRW3 Drägerwerk & Co. KGaA (pref) November 16, 2025
Drägerwerk AG & Co. KGaA (XETRA: DRW3) is a global medical- and safety-technology group that designs, manufactures, and services integrated system solutions for both healthcare and industrial risk-management markets. Its medical portfolio spans emergency medicine, peri-operative care, intensive care, and perinatal medicine, while its safety division supplies personal protection, gas-detection, and comprehensive risk-management products to industry, mining, fire services, police, and disaster-response agencies.
Key financial highlights (FY 2023) include €4.1 billion of revenue, an operating margin of roughly 9 %, and R&D spending at about 7 % of sales-reflecting the company’s emphasis on innovation in ventilators, anaesthesia machines, and advanced gas-sensing technology. Growth is driven by two macro-level forces: (1) sustained demand for high-performance medical ventilators and monitoring equipment in aging populations and post-pandemic hospital upgrades; and (2) tightening EU occupational-safety regulations that boost sales of personal-protective equipment and fixed-gas detection systems in the mining and manufacturing sectors.
If you want a data-rich, unbiased view of DRW3’s valuation multiples, cash-flow forecasts, and peer comparisons, the ValueRay platform provides a transparent dashboard that can help you extend your analysis.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (99.9m TTM) > 0 and > 6% of Revenue (6% = 201.6m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.17% (prev 25.12%; Δ -2.96pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 190.6m > Net Income 99.9m (YES >=105%, WARN >=100%) |
| Net Debt (269.5m) to EBITDA (315.7m) ratio: 0.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (18.8m) change vs 12m ago 0.04% (target <= -2.0% for YES) |
| Gross Margin 44.86% (prev 43.62%; Δ 1.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 111.7% (prev 110.9%; Δ 0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.93 (EBITDA TTM 315.7m / Interest Expense TTM 21.3m) >= 6 (WARN >= 3) |
Altman Z'' 4.12
| (A) 0.25 = (Total Current Assets 1.76b - Total Current Liabilities 1.01b) / Total Assets 2.99b |
| (B) 0.39 = Retained Earnings (Balance) 1.17b / Total Assets 2.99b |
| (C) 0.06 = EBIT TTM 169.1m / Avg Total Assets 3.01b |
| (D) 0.80 = Book Value of Equity 1.21b / Total Liabilities 1.52b |
| Total Rating: 4.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.89
| 1. Piotroski 6.0pt |
| 2. FCF Yield 8.20% |
| 3. FCF Margin 3.64% |
| 4. Debt/Equity 0.31 |
| 5. Debt/Ebitda 0.85 |
| 6. ROIC - WACC (= 1.92)% |
| 7. RoE 6.70% |
| 8. Rev. Trend 18.94% |
| 9. EPS Trend 61.70% |
What is the price of DRW3 shares?
Over the past week, the price has changed by -2.02%, over one month by +1.19%, over three months by +0.74% and over the past year by +51.51%.
Is DRW3 a buy, sell or hold?
What are the forecasts/targets for the DRW3 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 84 | 23.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 76.6 | 12.6% |
DRW3 Fundamental Data Overview November 27, 2025
Market Cap EUR = 1.26b (1.26b EUR * 1.0 EUR.EUR)
P/E Trailing = 10.7788
P/S = 0.3841
P/B = 0.8709
P/EG = 1.46
Beta = 0.542
Revenue TTM = 3.36b EUR
EBIT TTM = 169.1m EUR
EBITDA TTM = 315.7m EUR
Long Term Debt = 154.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 213.3m EUR (from shortTermDebt, last quarter)
Debt = 446.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 269.5m EUR (from netDebt column, last quarter)
Enterprise Value = 1.49b EUR (1.26b + Debt 446.9m - CCE 218.9m)
Interest Coverage Ratio = 7.93 (Ebit TTM 169.1m / Interest Expense TTM 21.3m)
FCF Yield = 8.20% (FCF TTM 122.2m / Enterprise Value 1.49b)
FCF Margin = 3.64% (FCF TTM 122.2m / Revenue TTM 3.36b)
Net Margin = 2.97% (Net Income TTM 99.9m / Revenue TTM 3.36b)
Gross Margin = 44.86% ((Revenue TTM 3.36b - Cost of Revenue TTM 1.85b) / Revenue TTM)
Gross Margin QoQ = 43.84% (prev 45.82%)
Tobins Q-Ratio = 0.50 (Enterprise Value 1.49b / Total Assets 2.99b)
Interest Expense / Debt = 1.20% (Interest Expense 5.35m / Debt 446.9m)
Taxrate = 29.73% (4.83m / 16.2m)
NOPAT = 118.9m (EBIT 169.1m * (1 - 29.73%))
Current Ratio = 1.74 (Total Current Assets 1.76b / Total Current Liabilities 1.01b)
Debt / Equity = 0.31 (Debt 446.9m / totalStockholderEquity, last quarter 1.46b)
Debt / EBITDA = 0.85 (Net Debt 269.5m / EBITDA 315.7m)
Debt / FCF = 2.21 (Net Debt 269.5m / FCF TTM 122.2m)
Total Stockholder Equity = 1.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.34% (Net Income 99.9m / Total Assets 2.99b)
RoE = 6.70% (Net Income TTM 99.9m / Total Stockholder Equity 1.49b)
RoCE = 10.28% (EBIT 169.1m / Capital Employed (Equity 1.49b + L.T.Debt 154.2m))
RoIC = 6.67% (NOPAT 118.9m / Invested Capital 1.78b)
WACC = 4.75% (E(1.26b)/V(1.71b) * Re(6.13%) + D(446.9m)/V(1.71b) * Rd(1.20%) * (1-Tc(0.30)))
Discount Rate = 6.13% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 81.65 | Cagr: 0.02%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈127.0m ; Y1≈83.4m ; Y5≈38.1m
Fair Price DCF = 87.14 (DCF Value 749.4m / Shares Outstanding 8.60m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 61.70 | EPS CAGR: 54.64% | SUE: 0.0 | # QB: 0
Revenue Correlation: 18.94 | Revenue CAGR: 0.36% | SUE: -0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=7.34 | Chg30d=+0.076 | Revisions Net=+0 | Growth EPS=+21.2% | Growth Revenue=+4.3%